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Moreover, HrQoL (DLQI) improved by 65% from inclusion. The conventional system-
ics cohort showed comparable reduction in PASI= 3.1 (77%) but less improvement 
in DLQI= 3.1 (49%). ConClusions: PsoBest provides long-term real-world data on 
psoriasis care in Germany. The results show the high burden of psoriasis patients 
entering the registry and also the high quality of care and patient benefit after 
initiation of systemic treatment.
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RecRuting PhySicianS foR health outcome and PoSt-aPPRoval 
StudieS: BenefitS of a managed PhySician Panel
Potthoff P.1, Güther B.1, Brown C.2, Eichmann F.1
1Kantar Health Germany, Munich, Germany, 2All Global, London, UK
objeCtives: Access to multi-country physician panels is an alternative option to 
recruit medical sites for health outcome or post-approval studies, compared to the 
conventional approach of individually recruiting clinical expert sites. The objec-
tive of our study was to assess the potential of physician panels for site recruit-
ment. Methods: In 2012, a representative survey among members of a managed 
physician panel (All Global’s managed panel of ophtalmologists in US, UK, GER, FR, 
IT and SP) was conducted. The survey assessed the willingness of the physicians 
to participate in post-approval studies. Information about former participation in 
those studies and commitment to special requests for post-approval studies (e.g. 
ethical committee involvement, advent reporting to sponsor, security of patient’s 
informed consent) were also collected. Results: A total of 200 opthalmologists 
participated in the survey. Since no special incentive was offered for participation 
the response rate of more than 25% was satisfactory. 79 (39,5%) of the physicians 
formerly participated in clinical trials and 95 (47,5%) in post-approval studies. 54,5% 
of the ophtalmologists were willing to participate in future studies. More than 80% 
of this group was ready to ask their hospital or other legal authorities for permission 
to participate in studies of this kind, to report serious adverse events to the spon-
sor of the study and to ask patients for written informed consent. ConClusions: 
Managed physician panels are a valuable alternative option to recruit medical sites 
for post-approval or health outcome studies. Every second ophtalmologist from 
panels is experienced in this kind of studies and most of them are willing fullfil all 
necessary legal and quality requirements. In addition to timing and cost factors, an 
adavantage of physician panels is the better representation of daily medical routine-
practice, adding to the epidemiological validity of respective projects.
PSS56
lymPhedema – the long Way to diagnoSiS and theRaPy
Blome C.1, Herberger K.1, Sandner A.1, Augustin M.2
1University Medical Center Hamburg, Hamburg, Germany, 2University Medical Center Hamburg-
Eppendorf, Hamburg, Germany
objeCtives: Clinical experience indicates that edema often remain undiagnosed. 
The aim of this study was to examine how much time passes between impor-
tant events in the ‘patient journey’ and what predicts late consultation and diag-
nosis. Methods: Sixty-five patients with secondary arm lymphedema and 161 
patients with primary or secondary leg lymphedema were interviewed. The follow-
ing latency times were computed: time between 1) first symptoms and first visit 
to physician; 2) visit to physician and diagnosis; 3) diagnosis and lymph drainage 
therapy; and 4) diagnosis and compression therapy. Associations of latency times 
with patient and clinical characteristics were analysed using t tests and multivari-
ate linear regression. Results: All arm edema patients had consulted a physician 
in the year after first symptoms at the latest, and everyone except two received the 
diagnosis in the following year at the latest. For secondary leg edema, the average 
latency until physician consultation was also short with 0.5 ± 1.8 years, and latency 
until diagnosis was 1.7 ± 3.8 years. In contrast, latencies in primary leg edema 
were significantly longer: The average time between first symptoms and physician 
consultation was 5.2 ± 11.0 years, and edema diagnosis was made after further 6.7 
± 11.4 years. On average, it took 13.5 years from first symptoms to lymph drainage 
therapy in these patients and 13.7 years until compression therapy. Predictors of 
late consultation and late diagnosis in primary leg edema were age< 40, positive 
family anamnesis, and female gender. ConClusions: Primary leg lymphedema 
are diagnosed late in many cases, especially in younger women.
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adheRence By SPaniSh RetinologiStS to the guidance foR 
the management of PatientS With Wet age-Related maculaR 
degeneRation
Colomé A.1, Balaña M.1, Ruiz Moreno J.M.2, Roura M.1
1Novartis Farmacéutica, S.A., Barcelona, Spain, 2Instituto Oftalmológico Alicante (VISSUM) y 
Universidad de Castilla la Mancha, Alicante, Spain
objeCtives: To assess the adherence by Spanish retinologists to the recommenda-
tions for the management of age-related macular degeneration (AMD) published by 
the Spanish Society of Retina and Vitreous (SERV). Methods: Non-interventional, 
retrospective and multicenter study, involving 59 researchers from different Spanish 
Ophthalmology Services that collected medical records from 346 patients aged ≥ 50 
years and diagnosed with exudative AMD. Results: Adherence to SERV-guidelines 
by Spanish retinologists was high concerning diagnostic (96.8%) and control items 
(98.6%) of AMD patients, slightly lower for therapeutic issues (84.4%), and much 
lower on patient follow-up and retreatment criteria (46.9%). When focusing on diag-
nostic, first symptoms indicative of wet AMD were sharp and progressive loss of 
visual acuity (64.7%), followed by metamorphopsia (distorted vision) (33.8%) and 
central scotoma (23.1%). Main diagnostic confirmatory tests were visual acuity 
(97.1%), OCT (93.4%), biomicroscopy (92.2%) and fluorescein angiography (71.1%). 
For therapeutic issues, first choice treatment was based on anti-VEGF-drugs (99.1%), 
mainly ranibizumab (96.8%) as a loading dose of three injections (88.1%). Main 
patient follow-up tests were: visual acuity tests (98.0%), optical coherence tomog-
raphy (96.0%), biomicroscopy (91.9%). Most common control schemes during the 
first year of treatment were every-two-months (35.8%) or monthly (30.4%) visits; 
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Safety in national caRe - Real WoRld data fRom the geRman 
PSoRiaSiS-RegiStRy “PSoBeSt”
Rustenbach S.J.1, Purwins S.1, Spehr C.1, Radtke M.A.1, Reich K.2, Augustin M.1
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Dermatologikum 
Hamburg, Hamburg, Germany
objeCtives: The registry “PsoBest” observes systemic therapy of moderate and 
severe psoriasis/psoriasis-arthritis in Germany since 2008. The registry is supported 
by the German society for dermatologists, the association of dermatologists, phar-
maceutical manufactures, dermatologists and patients. It is located at CVderm and 
documents safety, effectiveness and patient benefit in routine health care. One 
purpose of PsoBest is to monitor the safety of systemic antipsoriatics. Methods: 
Patients receiving first time a conventional systemic or biologic treatment are 
observed for 5 years, regardless of therapy switches. Standardised questionnaires 
for physicians and patients are compiled. Adverse and serious adverse events (AE/
SAE) are coded in MedDRA and analyzed twice a year. Results: Pharmacovigilance 
after 42 months on 1984 patients with 800 expositions to biologics (1196 patient 
years) and 1430 to systemics (1548 patient years) resulted in 187 SAE codings in 
121 patients (6.1%). A total of 105 SAE were observed under biologic and 95 under 
conventional systemic treatment (8.9 and 4.5%, respectively). Of these, 20 SAE in 14 
patients were observed in combined treatment. By system-organ-classes, general 
disorders and administration site conditions were observed for 2.3% of biologic 
(1.51 events/100 patient years) and 1.3% systemic patients (1.32 events/100 patient 
years). The rates for cardiac disorders were 0.92 (1.4% of patients) and 0.84 (0.9% 
of systemic patients), respectively. For infections and infestations the rates were 
0.84 (1.3%) and 0.52(0.8%) and for neoplasms benign, malignant and unspecified 
(incl. cysts and polyps) 0.67 (1.0%) and 0.71 (0.8%). ConClusions: PsoBest provides 
urgently needed long-term safety data in the systemic treatment of psoriasis and 
psoriatic-arthritis from routine care in Germany. To date, no safety concern emerged 
from the registry. To raise the power for signal detection, verification, analysis and 
assessment, PsoBest is proactively contributing to the European surveillance of 
effectiveness and safety of systemic psoriasis therapy (ENCEPP-network psonet).
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afliBeRcePt in neovaSculaR (Wet) age-Related maculaR 
degeneRation: an analySiS of the PayeR deciSion landScaPe
Brown A.1, Ferreira A.2, Lamle S.2, Milnes F.2
1Abacus International, Manchester, UK, 2Novartis Pharma AG, Basel, Switzerland
objeCtives: To investigate and analyse decisions of Health Technology Assessment 
or national drug reimbursement agencies for aflibercept in neovascular (wet) aged-
related macular degeneration, including decision outcomes, the rationale for these, 
the data package and any payer critique of the manufacturer approach. Methods: 
A search of decision-making agency websites in key European markets, Canada and 
Australia was conducted to identify relevant decisions. Data were extracted and used 
to conduct a qualitative analysis of decisions. Results: Five decisions were identi-
fied; from NICE (England & Wales), SMC (Scotland), HAS (France), G-BA (Germany) and 
PBAC (Australia). In all instances, the clinical and economic arguments, where appli-
cable, were based on demonstration of non-inferiority of aflibercept to an existing 
therapy, ranibizumab. These arguments were supported by two key trials of aflibercept 
vs. ranibizumab: VIEW 1 and 2, and also indirect comparisons and network meta-
analyses. In all decisions, aflibercept was either recommended for the full licensed 
indication or recommended with restrictions. All agencies commented that the key 
trials were well conducted and unbiased; however, they also state that the dosing 
schedule for ranibizumab did not reflect the license or clinical practice in respective 
markets, and it was unclear if there would be any difference in the frequency of 
injections between therapies in the clinical setting. Furthermore, for the economic 
models for NICE, SMC and PBAC, the respective agencies thought the frequency of 
injections and number of clinician visits for ranibizumab were overestimated. All 
agencies concluded that aflibercept demonstrated no additional clinical benefit over 
ranibizumab. For example, HAS in France granted an ASMR level V: no improvement 
in clinical benefit, while NICE recommended that aflibercept be used in accordance 
with their recommendations for ranibizumab. ConClusions: While aflibercept is 
an effective alternative therapy to ranibizumab, payers have concluded that it offers 
no demonstrable added clinical benefit compared with ranibizumab.
PSS54
health Related Quality of life-outcome in national caRe - Real 
WoRld data fRom the geRman PSoRiaSiS-RegiStRy “PSoBeSt”
Purwins S.1, Spehr C.1, Augustin M.1, Radtke M.A.1, Reich K.2, Rustenbach S.J.1
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Dermatologikum 
Hamburg, Hamburg, Germany
objeCtives: The registry “PsoBest” observes systemic therapy of moderate and 
severe psoriasis/psoriasis-arthritis in Germany since 2008. The registry is supported 
by the German society for dermatologists, the association of dermatologists, phar-
maceutical manufactures, dermatologists and patients. It is located at CVderm and 
records efficacy, safety, and patient benefit in routine health care. One purpose of 
PsoBest is to monitor health related quality of life (HrQoL) and severity of psoria-
sis in the process of care. Methods: Patients receiving first time a conventional 
systemic or biologic therapeutic are observed for 5 years, independent of further 
treatment. Standardised questionnaires for physicians and patients are compiled. 
Main outcomes are severity (PASI), affected body surface area (BSA) and HrQoL (DLQI 
and EQ-5D). Results: A total of 1,984 patients were enrolled up to July 2012 (60% 
male, mean age of 47 years); mean duration of illness was 19±14 years. Patients on 
biologics (n= 686) tended to be male (63 v. 58%), older (48.1 v. 46.7 years) as patients 
on conventional systemics (n= 1,298) and had a longer history of psoriasis (21.9 v. 
16.8 years). The biologic cohort showed more nail involvement (64 v. 52%), signs 
of arthritis (47 v. 17%), higher severity (PASI: 15.6 v. 14.6; BSA: 22. v. 21.5) and lower 
HrQoL (DLQI: 11.7 v. 11.0; EQ-5D VAS: 50.6 v. 55.7). For the biologics cohort, mean 
PASI improved to 4.5 between 12 and 24 months (reduction of 70% from baseline). 
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nel during standard-of-care visits. Although this is the traditional approach, it has 
several practical shortcomings: infrequent or irregular standard-of-care visits; 
patients switching health care providers; transient nature of some safety events; 
treatment at non-study sites, and the lack of care-seeking for the safety events. An 
alternative study design that overcomes several of these shortcomings includes 
direct-to-patient contact (DPC) and follow-up. objeCtives: The purpose of this 
study is to describe patients’ short and long term management patterns including 
the detection and verification of events of interest by contacting patients’ event 
treating physician (ETP). Methods: This is multinational multicenter observational 
prospective longitudinal cohort study involving 10,600 patients in Europe and South 
America. Patients were enrolled at hospital and followed up by telephone by a spe-
cialized DPC unit at 6 weeks then quarterly up to 2 years after hospital discharge. 
Data collected include clinical outcomes, safety events of interest, economic bur-
den and quality of life. Results: A total of 88,276 phone calls to patients were 
performed, achieving a reachable rate of 88.5% and an interview successful rate of 
84.6%. 87.2% of the initial sample completed the 2-year follow-up period: 5.7% of 
the sample died, 6.0% voluntarily withdrew and 0.9% was withdrawn to participate 
to a clinical trial. Only 19 patients were never reached (0.2%). In total, 2144 events of 
interest were detected and a medical verification from ETPs was obtained in 72.3% of 
the case. ConClusions: This study demonstrates that DPC along with a proactive 
pharmacovigilance system achieved very high response rates from both patients 
and ETPs. It represents an effective alternative methodology to collect patients data, 
including safety data, in real life settings.
Pcv3
antithRomBotic StRategieS and adveRSe outcomeS in acute 
coRonaRy SyndRome and atRial fiBRillation: a community Study
Chamberlain A.M.1, Gersh B.J.1, Klaskala W.2, Mills R.M.2, Alonso A.3, Weston S.A.1, Roger V.L.1
1Mayo Clinic, Rochester, MN, USA, 2Janssen Research & Development, LLC, Raritan, NJ, USA, 
3University of Minnesota School of Public Health, Minneapolis, MN, USA
objeCtives: Atrial fibrillation (AF) is frequent in acute coronary syndromes (ACS) 
and impacts the need for subsequent antithrombotic treatment. However, whether 
associations of antithrombotic treatment with strokes, bleeding, and death differ 
between ACS patients with and without AF remains uncertain. Methods: Olmsted 
County, MN residents with incident myocardial infarction or unstable angina during 
2005-2010 were classified according to AF status prior to or during the index ACS 
hospitalization. Antithrombotic strategy at discharge was categorized into double/
triple vs. no/single and warfarin vs. no warfarin therapy. Cox regression was used 
to examine associations between treatment and strokes, bleeding, and mortality 
and to test whether AF differentially impacted these associations. Models were 
age- and sex-adjusted and weighted for the inverse probability of the propensity 
score for therapy. Results: A total of 244 of 1140 incident ACS patients had AF 
(ACS+AF), and of these patients, 49% were discharged on double/triple antithrom-
botic therapy and 33% received warfarin. In 896 ACS patients without AF, 63% were 
discharged on double/triple therapy and 4% on warfarin. Over a median of 4.2 years, 
95 strokes, 297 bleeds, and 255 deaths occurred. Antithrombotic strategy was not 
associated with the risk of stroke or bleeding. Among all ACS patients, mortality 
was similar between strategies; however, ACS+AF patients on double/triple therapy 
(vs. no/single therapy) showed a trend toward a lower risk of death [HR (95% CI): 
0.64 (0.41-1.02) for ACS+AF, 1.25 (0.83-1.87) for those without AF; pinteraction= 0.03]. 
For warfarin vs. no warfarin, those with AF exhibited a lower mortality risk with 
warfarin [HR (95% CI): 0.46 (0.29-0.73) for ACS+AF, 2.01 (0.94-4.32) for those with-
out AF; pinteraction< 0.01]. ConClusions: Altogether, in community ACS patients, 
antithrombotic strategy is not associated with the risk of stroke, bleeding, or death. 
However, in the subset of ACS patients with AF, a warfarin strategy is associated 
with a lower risk of death.
Pcv4
comoRBidity influence in the contRol of aRteRial hyPeRtenSion
Sicras-Mainar A.1, Fernandez J.L.2
1Badalona Serveis Assistencials, Badalona, Spain, 2Primary Care Center Doctor Vicenç Papaceit, La 
Roca del Valles, Spain
objeCtives: Determine the impact of co-morbidity in controlling arterial hyperten-
sion in clinical practice situation. Methods: Cross-sectional study, conducted from 
retrospective review of patient records obtained from primary care. We included 
patients’ ≥ 30 years who demanded attention during the year 2012. The main meas-
ures were: demographics, control (≤ 140/90 mmHg) blood pressure (BP), evolution 
time, co-morbidity (general and specific) protocol using cardiovascular events (CVE), 
visits and referrals to specialists. Statistical analysis and multiple linear regression 
for correction of the models, p< 0.05. Results: We recruited 900 patients (mean age 
67.4 years, women: 51.1%). The 64.8% (CI: 61.7% -67.9%) of subjects had a proper 
control of the BP. The average duration of hypertension was 6.0 years and use 4.6 
protocol entries / year. The average number of visits was 15.3 and 0.7 referrals. The 
years of evolution were associated with age (r = 0.323). The control patients showed 
a higher average BP of ischemic heart disease (11.1% vs. 6.9%) and CVE (19.4% vs. 
14.8%), p < 0.05. The BP control was associated with women (OR = 1.4) and the pres-
ence of CVE (OR = 1.8), p < 0.02. The number of diagnoses (morbidity) was associated 
with age (ß = 0.14) and the number of referrals (ß = 0.08), p < 0.05 (coefficient R2= 
40%). ConClusions: Optimal control of BP is high. The profile of these patients is 
women in a situation of secondary prevention.
Pcv5
high doSageS of StatinS in high caRdiovaSculaR RiSk PatientS in a 
Real WoRld Setting: tReatment PatteRnS and outcomeS
Degli Esposti L., Sangiorgi D., Buda S.
CliCon Srl, Ravenna, Italy
objeCtives: International guidelines recommend the use of high dosages statins 
(in particular, Rosuvastatin and Atorvastatin) in high cardiovascular (CV) risk 
patients. The aim of this study was to assess the degree of implementation of the 
while after first year of treatment, controls tend to become less frequent, mostly 
every-three-months (39.9%). When recurrence occurs, main retreatment criteria 
were: presence of macular fluid (93.5%), loss of ETDRS letters (50.5%; 68.8% with 
≥ 5 letters), macular hemorrhage (46.3%) and increase of central-retinal-thickness 
(45.4%). Single injection of anti-VEGF retreatments was applied in 48.6% of recur-
rences, while 23.6% were not treated with anti-VEGF. ConClusions: A relatively 
high adherence to SERV guidelines was followed by Spanish retinologists regarding 
diagnosis, treatment and control of AMD. However, limitations have been identified 
on patterns of follow-up and retreatment criteria that may compromise therapeutic 
and clinical outcomes.
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tReatment PatteRnS of RaniBizumaB and afliBeRcePt foR the 
management of Wet age-Related maculaR degeneRation in Routine 
clinical PRactice in the united StateS
Ferreira A.1, Sagkriotis A.1, Milnes F.1, Olson M.1, Hill J.2, Lu J.2, Makin C.2
1Novartis Pharma AG, Basel, Switzerland, 2IMS Health, Plymouth Meeting, PA, USA
objeCtives: To compare the frequency of injections for ranibizumab and afliber-
cept for the treatment of wet age-related macular degeneration (wAMD) in a real-
world setting. Methods: Claims from the IMS Integrated Data Warehouse were 
used to identify treatment-naïve patients with wAMD receiving ≥ 1 prescription for 
ranibizumab or aflibercept between 1 November 2011 and 31 March 2012 and with 
a follow-up of 365 days. Patients were considered to be treatment-naïve if they had 
received no anti-VEGF treatment for > 180 days prior to the index date. Mean number 
of injections received within 365 days of treatment initiation and the proportion of 
patients receiving 3 loading doses within 3 months were calculated and compared 
for patients starting therapy with ranibizumab or aflibercept. No adjustments for 
bilateral treatment were performed. Results: Patient characteristics were similar 
for patients receiving ranibizumab (N= 2,799) or aflibercept (N= 117) at the index 
date (median age: 82 years; % male, 36%). The mean (±SD) number of anti-VEGF 
injections received by patients starting on ranibizumab or starting on aflibercept 
was similar: 5.6±3.5 and 5.4±2.8, respectively (p= 0.6593). In patients continuously 
treated with the same agent for 12 months, the mean number of injections was 
also similar across ranibizumab and aflibercept: 4.9±3.4 (n= 1,898) vs 5.2±2.6 (n= 87), 
respectively (p= 0.2705). Approximately two-thirds of patients with more than 3 
injections received 3 loading doses within the first 3 months (ranibizumab, 65.6%; 
aflibercept, 64.3%). Results for patients who were treatment-naïve for 365 days were 
consistent with the above results. ConClusions: There are limited data regard-
ing real-world treatment patterns with aflibercept for the management of wAMD. 
Our results suggest that in routine clinical practice patients receive a comparable 
number of injections in the first year of treatment with both ranibizumab and 
aflibercept. Analysis of data from larger patient populations and for longer follow-
up is warranted when these data become available.
ReSeaRch PoSteR PReSentationS – SeSSion iv 
diSeaSe-SPecific StudieS 
caRdiovaSculaR diSoRdeRS – clinical outcomes Studies
Pcv1
aPPlication of logiStic RegReSSion foR Signal detection and RiSk 
aSSeSSment of macRolide-aSSociated toRSade de PointeS
Ali A.K.
Eli Lilly and Company, Indianapolis, IN, USA
objeCtives: Torsade de pointes (TdP) is an identified risk for antibacterial treat-
ment with macrolides, but the risk might vary across individual macrolides. This 
study evaluates the association between macrolides and TdP from the FDA Adverse 
Event Reporting System (FAERS). Methods: Disproportionality analysis of FAERS 
between 1997 and 2012 was conducted for azithromycin, clarithromycin, erythro-
mycin and Telithromycin with TdP preferred term of the Medical Dictionary for 
Regulatory Activities using logistic regression. Logistic reporting odds ratio (LROR) 
and corresponding 95% confidence intervals (CIs; LR05-LR95) are estimated for 
individual macrolides. Estimates are compared with Multi-Item Gamma Poisson 
Shrinker data mining algorithm. Estimates ≥ 2 yield significant safety signals. Lack 
of overlap between estimate-specific CIs indicates efficient approach for signal 
detection. Results: A total of 318 TdP events were reported for macrolides. The 
majority of reports were for erythromycin (n= 122) and clarithromycin (n= 114), fol-
lowed by azithromycin (n= 74) and telithromycin (n= 8). Most of events were reported 
for females with median age of 62.8 years. 98% of TdP were serious events (10% of 
those were deaths). Death contributed to 18%, 10% and 5% of serious TdP events 
for azithromycin, erythromycin and clarithromycin, respectively. Telithromycin 
didn’t have death TdP reports. Significant TdP signals were identified for mac-
rolides. LROR (LR05-LR95) were: erythromycin 48.1 (40.4-55.9); clarithromycin 15.3 
(12.1-19.1); azithromycin 13.9 (11.1-17.2); and telithromycin 6.79 (3.20-13.5). Except 
for telithromycin, no overlap was observed between estimate-specific CIs between 
analysis methods. ConClusions: Macrolides are associated with more than 
expected reporting of TdP compared to other drugs and events in the database; 
however, the risk was highest in erythromycin and lowest in telithromycin. Fatal TdP 
was highest in azithromycin, and telithromycin didn’t have fatal TdP. The findings 
show differential risk of TdP across macrolide antibiotics, emphasizing the need for 
monitoring cardiac rhythms in patients treated with macrolides.
Pcv2
diRect-to-Patient contact and PRoactive PhaRmacovigilance 
SyStem: a caSe Study
Wiederkehr S., Seux M., Michel J., Fournie X.
Mapi, Lyon, France
Post-authorization non-interventional safety studies typically enroll patients at 
sites and safety events are reported and collected as appropriate by site person-
